Author: Gonzalo Alvaro

Schizophrenia is a complex chronic disorder is associated with significant functional impairment and high personal and social costs. Likewise it is compounded by a high rate of comorbidities, such as cardiovascular diseases, leading to isolation and a progressive worsening of the condition.

On 24 May, World Schizophrenia Day, we at ROVI would like to shine a spotlight on people, their wellbeing, and the importance of continuing to construct increasingly humane, accessible and recovery-oriented care.

A reality that requires attention

The latest data, gathered in the Global Burden of Disease Study 2021, provide a clear picture of the scale of the challenge: over 23.2 million people all over the world live with schizophrenia, representing around 0.3% of the global population. Global prevalence stands at 293.8 cases per 100,000 inhabitants, with 332.5 cases per 100,000 inhabitants in Spain. Beyond the figures, one of the main challenges in managing schizophrenia continues to be maintaining good treatment adherence, a key factor in reducing relapses and hospital readmissions that impair patients’ functioning and quality of life.

Our commitment: to support, research and improve

At ROVI, we maintain a sustained commitment to the research and development of innovative solutions in the mental health field. Our ISM® technology forms part of this effort and has led to developments that are already available in various markets.

At the same time, we continue to work on new formulations in research, with the aim of further expanding the options available in the future. This commitment involves continuing to research, collaborating with healthcare professionals, and always placing patients at the centre of our work.

ROVI presents its financial results for the first quarter of 2026, a year in which the Company expects to resume a path of growth, supported by the key strategic decisions taken over recent years.

REVENUES

Total revenue stood at €154.7 million in the first quarter of 2026. ROVI booked operating revenue of 152.5 million euros, representing a 2% decrease on the first quarter of 2025 due to the behaviour of the heparin franchise. Notwithstanding, the contract manufacturing business (CDMO) recorded sales of 37.4 million euros, a 5% increase on the first quarter of 2025.

The sales of the specialty pharmaceutical business stood at €115.0 million in the first quarter of this year.

Sales of the low-molecular-weight heparin franchise dropped 13% to 58.9 million euros, due to a lower contribution from bemiparin, particularly in international sales, as a result of the high inventory levels held by partners.

Risperidone ISM stands out, with sales reaching 17.2 million euros, showing growth of 37% compared with the same quarter of 2025.

Solid performance of Neparvis®, with sales growing by 4% in the first quarter of this year.

Gross profit increased 5% to 95.0 million euros in the first quarter of 2026 compared with the first quarter of 2025, reflecting a 3.8 percentage point increase in the gross margin, which rose to 62.3%.

EBITDA stood at 20.3 million euros in the first quarter of 2026. This has led to a 6.3 percentage point reduction in the EBITDA margin to 13.3%. Net profit stood at 9.4 million euros.

R&D expenses rose 75% in the first quarter of 2026 compared with the same period of last year. This increase relates mainly to preparations for the phase III clinical trial of Letrozole SIE.

ROVI has updated its operating revenue guidance for 2026 . expecting them to continue to increase compared to 2025, although by a low- to mid-single-digit percentage. Factors taken into account for this revision include:

• Firstly, lower revenue forecast for 2026 under the prefilled syringe manufacturing agreement entered into with a global pharmaceutical company on 25 April 2024. The adjustment to the guidance is due, among other factors, to a delay in the initially expected commencement of routine manufacturing operations, which is awaiting the relevant regulatory authorization, as well as increased uncertainty regarding anticipated demand, without prejudice to the minimum contractual obligations assumed by the two parties; and

• Secondly, growing competitive pressure on pricing in the heparin franchise in the current context of increased regulatory and geopolitical uncertainty and greater volatility in supply and cost dynamics.

ROVI announces its financial results for the full year 2025, an inflection point in which took strategic steps forward to reinforce its international reach and ensure the company’s long-term creation of sustainable value.

• Acquisition of a manufacturing facility for injectable pharmaceuticals in Phoenix, Arizona (USA) to Bristol Myers Squibb and a Toll Manufacturing Agreement, which regulates the conditions under which ROIS Phoenix Inc. will continue to manufacture for BMS at the facility.

• ROVI will also collaborate with Roche for the manufacture of a new medicine, currently in the clinical development phase, from it’s metabolic and cardiovascular portfolio.

Total revenue in 2025 was 756.1 million euros, a 1% decrease on 2024. ROVI booked operating revenue of 743.5 million euros, representing a 3% decrease on 2024, due to the behaviour of the contract development and manufacturing business (CDMO).

In addition, the contract manufacturing business (CDMO) booked sales of 269.5 million euros.

Notwithstanding, sales of the specialty pharmaceutical business rose 11% to 473.9 million euros this year.

Risperidone ISM® continues its strong growth reaching total sales of 56.7 million euros. This represents a 97% increase over sales registered on 2024.

Sales of the heparin franchise, which includes low-molecular-weight heparins and other heparins, increased 7% to 266.8 million euros, due to the increase in orders from international partners. The main contributor to the division’s growth was enoxaparin, sales of which rose 9% to 157.7 million euros as a result of an increase in orders from partners during 2025. Bemiparin sales increased by 4% in 2025 in comparison to 2024.

Gross profit increased 3% to 494.7 million euros in 2025, reflecting an increase of the gross margin of 3.9 percentage points to 66.5% in 2025.

Likewise, in 2025 EBITDA increased to 216.2 million euros, reflecting a 1.9 percentage point rise in the EBITDA margin, which reached 29.1% in 2025.

Net profit rose 3% to 140.4million euros..

For 2026, ROVI expects operating revenue to increase by between a high single-digit and low double-digit percentage.

ROVI announces its financial results for the first nine months of 2025, a period in which it took strategic steps forward to reinforce its global reach and accelerate its growth.

One of the most significant milestones was the acquisition of a manufacturing facility for injectable pharmaceuticals in Phoenix (USA) from Bristol Myers Squibb (BMS), which positions ROVI as a global industrial player with direct presence in the United States market. In addition, as part of the transaction, a Toll Manufacturing Agreement has been signed with BMS, which regulates the conditions for continuing with the manufacture of its products at this facility.

Likewise, ROVI has announced that it will collaborate with Roche in the manufacture of a new medicine, currently in the clinical development phase, from Roche’s metabolic and cardiovascular portfolio.

ROVI booked operating revenue of 525.1 million euros, representing a 7% decrease on the first nine months of 2024, due to the behaviour of the contract manufacturing business.

Notwithstanding, sales of the specialty pharmaceutical business rose 10% to 343.4 million euros in the first nine months of the year.

Risperidone ISM® maintained its positive evolution, reaching total sales of 41.0 million euros in the first nine months of the year. This represents a 102% increase on the first nine months of 2024.

Sales of the heparin franchise, which includes low-molecular-weight heparins and other heparins, increased 7% to 189.8 million euros due to the increase in orders from international partners. The main contributor to the division’s growth was the enoxaparin biosimilar, sales of which rose 11% to 112.8 million euros in the first nine months of 2025 as a result of an increase in orders from partners during the period.

In addition, the contract manufacturing business (CDMO) booked sales of 181.7 million euros.

In the first nine months of 2025, the gross margin increased by 3.5 percentage points compared to the same period of 2024, reaching 67.1%.

Likewise, in the first nine months of 2025, EBITDA decreased 11% to 149.5 million euros.

Net profit was 97.7 million euros.

For 2025, ROVI expects operating revenue to decrease by a mid-single-digit percentage.

For 2026, ROVI expects its operating revenue to increase by between a high single-digit and low double-digit percentage compared to 2025.

This estimate is based on a number of factors whose evolution is difficult to predict, such as:

– Limited visibility of the evolution of the demand and production associated with the 2026 vaccination campaign,

– The potential revenue from the manufacturing agreement signed with Bristol Myers Squibb (still in the process of signature) as part of the transaction announced on 29 September 2025, and

– Revenues derived from other agreements related to contract manufacturing activities.

This Wednesday, Laboratorios Farmacéuticos Rovi, S.A. held its Ordinary General Shareholders’ Meeting, at which all the items on the agenda were approved, including the annual accounts for 2024 and the shareholder remuneration via dividend. Specifically, the Meeting, which reached a quorum on the first call, approved the distribution of a dividend of 0.9351 euros per share entitled to receive it, equivalent to a maximum of 47,910,561.05 euros, charged to the 2024 profit, representing a pay-out of 35% of ROVI’s consolidated net profit.

The 2025 General Shareholders’ Meeting was attended by 397 shareholders, both present and represented, holding a total of 44,104,081 shares, accounting for 86.081% of the Company’s share capital. The strong support received at the Meeting reflects the shareholders’ confidence in the current management team and the Company’s long-term growth strategy, with special focus on internationalisation, driving the contract manufacturing business (CDMO) forward and promoting innovation and the development of own products using the ISM® technology, such as Okedi® (Risperidone ISM®).

Mr Juan López-Belmonte Encina said: “2024 was a key year of transition in laying the foundations for our future. We focused on strengthening our capacity in the contract manufacturing area to address the imbalance between the growing demand and the limited supply of production capacities for injectables. The expansion of our production capacities places us in a favourable position to meet global market needs. Furthermore, Risperidone ISM® showed efficacy in treating schizophrenia with positive results that are reflected in an improvement in the patients’ quality of life. We are continuing to invest in research and development, taking advantage of the capabilities of our ISM® technology to provide innovative solutions that drive the well-being of society forward and help medicine to advance.”

Churriana de la Vega hosted the 9th edition of the Churriana Integra Race, a benchmark event in the field of adapted sports in the province of Granada. Of course, Team ROVI Granada could not miss the competition, organised by the Granada Integra Foundation, which had more than 1,000 runners registered

A special route around the Air Base

This year, due to the works that prevented the normal circuit of previous editions, the Churriana Integra Race included in one of its sections the Armilla Air Base, being able to run through an area hitherto unexplored in the event and making this year a special occasion.

A celebration of sport and inclusion

The City Council of Churriana de la Vega and the Granada Integra Foundation wanted to close the event with a solidarity paella for all participants, demonstrating that sport brings people together and motivates us to get the best out of ourselves.

Don’t miss the video of the event!

ROVI lays the foundations for its future growth: it forecasts that its contract manufacturing business sales will double by 2030.

• ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase in its contract manufacturing business sales.
• The company will reinforce its current position as one of the major global leaders in the fill and finish of injectables after expanding its installed capacity.
• ROVI expects the specialty pharmaceutical division to grow annually by a low-single-digit percentage in the period from 2024 to 2030, with Okedi® as the primary growth driver.
• The company plans to commence the next phases of the clinical development of Letrozole SIE and three-monthly risperidone.

You can watch the presentation of the Capital Markets Day ROVI 2025 in this video.

Laboratorios Farmacéuticos ROVI announces the full-year results for 2024, a key year for setting the bases for ROVI’s future, focused on increasing our production capacities in the contract manufacturing business and reinforcing the company’s internationalisation with Risperidone ISM®.

In 2024, the company obtained operating revenue of 763.7 million euros; EBITDA of 207.4 million euros; and a net profit of 136.9 million euros.

The contract manufacturing business (CDMO) decreased 18% compared to 2023, dropping to 336.2 million, as a consequence of:

– lower revenue related to the manufacture of the COVID-19 vaccine compared with 2023, when ROVI booked higher revenue related to the production of the “pandemic” COVID-19 vaccine; and – lower revenue related to the activities carried out to prepare the plant for vaccine production under the agreement with Moderna.

Positive evolution of Okedi® (Risperidone ISM®), which had total sales of 28.8 million euros in 2024. Okedi® sales in 2024 doubled those of 2023.

Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) slightly decreased by 1% to 248.7 million euros in 2024, mainly due to lower orders from enoxaparin partners throughout the year.

In December 2024, for the fifth year running, ROVI improved its ESG risk rating awarded by Sustainalytics, achieving a low risk of 16.1, compared to 16.4 the previous year. The Company was placed fifth in the world ESG risk ranking from among the 424 companies evaluated in the pharmaceutical industry.

Financial donation of 250,000 euros for the reconstruction of damaged areas

We are pleased to announce that Laboratorios Farmacéuticos ROVI has made a donation of 250,000 euros to the solidarity account set up by the Generalitat Valenciana for the repair of damage and reconstruction of the areas affected by the DANA of 29th of October.

This contribution is part of the actions that the company carries out in emergency and humanitarian situations through the group’s Donations Committee. In this case, the funds will be used to repair the serious material damage caused in numerous urban and rural areas of the province of Valencia as a result of the intense rainfall and floods.

With this collaboration, we hope to contribute to a speedy recovery of the affected areas and the restoration of normal daily life.

Today, 25 November, is the International Day for the Elimination of Violence against Women.

At ROVI we do not tolerate harassment and we reject any form of violence, physical, sexual, psychological or moral harassment, abuse of authority at work or any other form of harassment or conduct that creates an intimidating or offensive environment for the rights of our employees.

ROVI also has an internal information system (Ethics Channel) which allows for fluid and effective communication with the bodies responsible for ensuring compliance with the company’s Code of Ethics, guaranteeing confidentiality and non-retaliation in the event of any type of harassment, abuse or violence suffered by a ROVI employee.